Who are intrapleural minocycline instillation's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Vibramycin, Doxycycline Tablets, Doxycycline pre-operatively, topical tetracycline, Interferon beta 1a, oral doxycycline, tetracycline (BQ10).

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/intrapleural-minocycline-instillation.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-16 · How we verify

intrapleural minocycline instillation — Competitive Intelligence Brief

intrapleural minocycline instillation (intrapleural minocycline instillation) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: tetracycline antibiotic. Area: Infectious Disease.

phase 3 tetracycline antibiotic Infectious Disease Small molecule Live · refreshed every 30 min

Target snapshot

intrapleural minocycline instillation (intrapleural minocycline instillation) — National Taiwan University Hospital. Minocycline has antimicrobial properties that may help reduce inflammation and prevent infection in the pleural space.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
intrapleural minocycline instillation TARGET	intrapleural minocycline instillation	National Taiwan University Hospital	phase 3	tetracycline antibiotic
Vibramycin	doxycycline	Generic (originally Pfizer)	marketed	Tetracycline antibiotic	72 kDa type IV collagenase, Stromelysin-1, Collagenase 3	1967-01-01
Doxycycline Tablets	Doxycycline Tablets	Yaounde Central Hospital	marketed	Tetracycline antibiotic	Bacterial 30S ribosomal subunit
Doxycycline pre-operatively	Doxycycline pre-operatively	University of Pittsburgh	marketed	Tetracycline antibiotic	Bacterial 30S ribosomal subunit
topical tetracycline	topical tetracycline	Johns Hopkins University	marketed	Tetracycline antibiotic	Bacterial 30S ribosomal subunit
Interferon beta 1a, oral doxycycline	Interferon beta 1a, oral doxycycline	Louisiana State University Health Sciences Center Shreveport	marketed	Cytokine + tetracycline antibiotic combination	Interferon-beta receptor (IFNBR); doxycycline targets bacterial ribosomes and matrix metalloproteinases
tetracycline (BQ10)	tetracycline (BQ10)	National Taiwan University Hospital	marketed	Tetracycline antibiotic	Bacterial 30S ribosomal subunit

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

2027-12-19 — Vibramycin · 7749532 · Formulation · US

Sponsor landscape (tetracycline antibiotic class)

BioPharmX, Inc. · 2 drugs in this class
Hospital General de Mexicali · 1 drug in this class
Laboratorios Goulart S.A. · 1 drug in this class
National Taiwan University Hospital · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). intrapleural minocycline instillation — Competitive Intelligence Brief. https://druglandscape.com/ci/intrapleural-minocycline-instillation. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab